American Association for Cancer Research
00085472can192924-sup-229237_2_supp_5894011_q0tq9r.jpeg (1.92 MB)

Figure S5 from A Versatile ES Cell–Based Melanoma Mouse Modeling Platform

Download (1.92 MB)
posted on 2023-03-31, 03:22 authored by Ilah Bok, Olga Vera, Xiaonan Xu, Neel Jasani, Koji Nakamura, Jordan Reff, Arianna Nenci, Jose G. Gonzalez, Florian A. Karreth

This Figure shows the percent of melanomas expressing ectopic Pten or GFP, and the expression of rtTA3 in Pten-restored tumors.



The cumbersome and time-consuming process of generating new mouse strains and multiallelic experimental animals often hinders the use of genetically engineered mouse models (GEMM) in cancer research. Here, we describe the development and validation of an embryonic stem cell (ESC)-GEMM platform for rapid modeling of melanoma in mice. The platform incorporates 12 clinically relevant genotypes composed of combinations of four driver alleles (LSL-BrafV600E, LSL-NrasQ61R, PtenFlox, and Cdkn2aFlox) and regulatory alleles to spatiotemporally control the perturbation of genes of interest. The ESCs produce high-contribution chimeras, which recapitulate the melanoma phenotypes of conventionally bred mice. Using the ESC-GEMM platform to modulate Pten expression in melanocytes in vivo, we highlighted the utility and advantages of gene depletion by CRISPR-Cas9, RNAi, or conditional knockout for melanoma modeling. Moreover, complementary genetic methods demonstrated the impact of Pten restoration on the prevention and maintenance of Pten-deficient melanomas. Finally, we showed that chimera-derived melanoma cell lines retain regulatory allele competency and are a powerful resource to complement ESC-GEMM chimera experiments in vitro and in syngeneic grafts in vivo. Thus, when combined with sophisticated genetic tools, the ESC-GEMM platform enables rapid, high-throughput, and versatile studies aimed at addressing outstanding questions in melanoma biology.Significance: This study presents a high-throughput and versatile ES cell-based mouse modeling platform that can be combined with state-of-the-art genetic tools to address unanswered questions in melanoma in vivo.See related commentary by Thorkelsson et al., p. 655

Usage metrics

    Cancer Research



    Ref. manager